The FDA has accepted a supplemental new drug application (sNDA) seeking approval for selinexor (Xpovio) for the treatment of patients with multiple myeloma following at least 1 previous line of therapy.
Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.
Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.
Oncology nurses play a vital role in informing patients about the importance of molecular testing and brain imaging in EGFR-mutated lung cancer.
The FDA’s Oncologic Drugs Advisory Committee voted in favor of minimal residual disease as an end point to support accelerated approval of multiple myeloma treatments.
Patients with renal cell carcinoma who did not undergo surgical resection and were treated with stereotactic ablative body radiotherapy experienced high local control rates with…
Patients with metastatic microsatellite stable colorectal cancer treated with a personalized neoantigen cancer vaccine after chemotherapy demonstrated an early trend towards a progression-free survival benefit.
One expert explains the importance of deciphering the data obtained through wearable technology while aiming to avoid data fatigue in oncology nurses.
Advanced care planning can benefit both the patients with cancer and the oncology nurses who work in intensive care units, as it may potentially reduce…
Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.
One expert explains the importance of deciphering the data obtained through wearable technology while aiming to avoid data fatigue in oncology nurses.
